INTRODUCTION
Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells. 1 Globally, over 80 000 new cases of MM are reported each year, representing~1% of all new cancer cases and 10% of all hematologic malignancies. 2, 3 The incidence of MM increases with age, indicative of the accumulation of epigenetic/genetic changes during the typical development of the disease from monoclonal gammopathy of undetermined significance, through smoldering (asymptomatic) myeloma, to symptomatic MM. 4 Clinically, symptomatic MM is characterized by end-organ damage, generally involving hypercalcemia, renal failure, anemia and bone marrow lesions (CRAB features). 5 Skeletal pain and fatigue are common symptoms of MM, and can severely impact the patient's quality of life. 6 The overall median survival is~5-6 years from diagnosis of MM, 7 yet disease outcomes are strongly influenced by the characteristics of the cancer (for example, high-risk cytogenetics) and/or the patient (for example, age). In younger patients, autologous stem cell transplantation has led to improved progression-free survival (PFS) and overall survival (OS). 8, 9 Here, patients receive induction therapy, which is typically a combination regimen based on an alkylating agent and/or a proteasome inhibitor (PI; for example, bortezomib [BORT] and carfilzomib [CAR] ) and/or an immunomodulatory drug (IMiD; for example, lenalidomide [LEN] , thalidomide [THAL] and pomalidomide [POM] ), to reduce disease burden before high-dose chemotherapy and stem cell transplantation. As mentioned, however, MM is most prevalent in elderly patients, the majority of whom are ineligible for autologous stem cell transplantation. Induction therapy with novel agents has also improved survival in this population, although management of elderly patients is often complicated by comorbidities. 10 Regardless of eligibility for autologous stem cell transplantation, maintenance therapy using novel agents is typically administered with the intention of sustaining disease response.
The development of novel agents over the past decade has improved outcomes in patients with MM, 7 although the vast majority of patients will eventually relapse. Outcomes are generally worse for patients who have failed currently available treatments, with a median OS of 9 months estimated for patients who are refractory to PIs and IMiDs. 11 As such, there is an unmet need for new therapies to increase survival for patients with MM. The demand is clearly high in patients with relapsed and/or refractory MM (RRMM) who have exhausted current treatment options, yet there is also an opportunity to attain deeper and more sustained response in front-line, or early-line, therapy. Tolerability is also a limitation of current treatments, [12] [13] [14] particularly in the increasing elderly population with MM who are generally more susceptible to adverse events (AEs). Indeed, careful selection and management of patients with RRMM has been recommended to optimize the benefits of current treatments. 15 As such, reduced toxicity would be a key attribute for new agents to facilitate their use in a greater proportion of patients. The corollary of these unmet treatment needs is the extensive pipeline of anti-MM drugs, focused on delivering new agents with novel modes of action.
Of the spectrum of new agents in development for the treatment of MM, monoclonal antibodies (mAbs) have emerged as a potential strategy based on the range of antigens highly expressed on the surface of the malignant cell ( Figure 1) . In other cancers, mAb-based therapy is already established, with 410 antibodies having received approval from the FDA for solid or hematologic malignancies since 1997. 16 Antibodies afford a targeted approach to treatment, with toxicity directed primarily against the malignant cell. Antibodies are also associated with a favorable tolerability profile, as most of the approved agents have different and less severe toxicities compared with standard chemotherapeutics. 16 In this review, we evaluate the promise of targeted therapy for MM in light of the key clinical data, focusing on the exciting recent developments in mAb-based therapy for this disease.
CD38
CD38 is a multifunctional cell surface glycoprotein that serves as both a receptor for the transduction of activation/proliferation signals and an ectoenzyme that catalyzes the production of nucleotides involved in calcium signaling ( Figure 2 ). 17 As a receptor, CD38 engages the non-substrate ligand CD31, which is thought to elicit an intracellular signaling cascade via ZAP-70 and ERK1/2. 17 As an ectoenzyme, CD38 catalyzes the conversion of nicotinamide adenine dinucleotide to cyclic adenosine diphosphate ribose, and is also involved in the hydrolysis of cyclic adenosine diphosphate ribose to adenosine diphosphate ribose. 18 In MM, the operation of CD38 with fellow ectoenzymes PC-1 and CD73 has been postulated to enhance MM survival through the production of adenosine which can modulate the immune response. 19 The ectoenzyme activity of CD38 also appears important in other malignancies, with postulated roles in proliferation and migration in chronic lymphocytic leukemia.
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CD38 expression is low in the normal bone marrow compartment, except on committed bone marrow progenitor cells. However, CD38 is highly expressed in 480% of cases of MM 21 and serves as a marker for MM cells.
There are presently three anti-CD38 mAbs in clinical development for the treatment of MM: daratumumab (DARA), SAR650984 and MOR202.
Daratumumab DARA was generated from immunization of human transgenic HuMab-mice with recombinant CD38 protein. 22 In preclinical models, DARA was shown to elicit cell death through four mechanisms: antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibodydependent cellular phagocytosis (ADCP) and apoptosis via crosslinking (crosslinkage with Fc receptors or anti-human IgG antibody). [22] [23] [24] [25] ADCC was observed in all CD38+ MM cell lines, whereas CDC appeared dependent on CD38 expression level. 22, 24 The anti-tumorigenic potential of DARA has also been explored in combination with other novel and established agents. Here, increased cell lysis was observed when DARA was added to LEN and/or BORT, or to the established triplet regimen of melphalan (MEL)-prednisone (PRED)-BORT. [26] [27] [28] The clinical data reported for DARA have largely been from the phase I/II trials in patients with RRMM, either as monotherapy (NCT00574288; NCT01985126) or in combination with LEN and dexamethasone (DEX) (NCT01615029). In the expansion phase of the initial monotherapy trial, efficacy appeared dose related: the overall response rate (ORR; at least a partial response (PR)) was 10% for patients who received the 8 mg/kg dose and 35% for patients who received the higher 16 mg/kg dose ( Table 1) . 29 Median PFS was also longer in the high-dose cohort (23 vs 14.9 weeks), although these data were immature at the time of presentation (May 2014). 29 The apparent dose-response relationship is supported by pharmacokinetic (PK) data, which suggest that target-mediated clearance of this agent is reduced at higher doses, 30 and the 16 mg/kg dose is being advanced in phase III trials. Results at the 16 mg/kg dose have also been recently presented from the second monotherapy trial (SIRIUS), testing daratumumab in 106 patients who had received at least three prior lines of therapy or were refractory to their most recent PI and IMiD combination. 31 The ORR was 29% in this heavily pre-treated population (median of five prior therapies; 95% refractory to last PI and IMiD), with a median duration of response of 7.4 months. An ORR of~20-30% was observed across subgroups (for example, according to age (⩾75 years) or renal function (creatinine clearance ⩾ 60 ml/min)), and irrespective of the agent(s) to which patients were previously refractory. The median PFS in this study was 3.7 months, and the estimated 1-year survival rate was 65%. 31 In the combination study of DARA plus LEN and DEX in a moderately pre-treated population (median of two prior lines of Figure 2 . CD38 mode of action. ADCC, antibody-dependent cellmediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; ADPR, adenosine diphosphate ribose; cADPR, cyclic adenosine diphosphate ribose; CDC, complement-dependent cytotoxicity; mAb, monoclonal antibody; MAC, membrane attack complex; MM, multiple myeloma; NAADP, nicotinic acid adenine dinucleotide phosphate; NAD+, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; NK, natural killer. therapy), the ORR was 91% (39/43) across the dose escalation and expansion phases. 32 The majority of these patients (n = 30) were assessed in the dose expansion phase at DARA 16 mg/kg, with ORR 87% in this section of the study. 32 A high proportion of patients assessed in this combination study had received prior IMiD treatment (80%), although it should be noted that only 7% of the total population were refractory to LEN. 32 Most recently, data have been released from an open label, phase Ib study of DARA in combination with a range of established backbone therapies (NCT01998971). Patients with newly diagnosed disease were treated with DARA plus BORT-DEX (n = 6), BORT-MEL-PRED (n = 8) or BORT-THAL-DEX (n = 11), with all those evaluable achieving at least PR. 33 The addition of DARA to POM-DEX was assessed in 24 patients with RRMM, with ORR 55% in the 11 patients available for efficacy assessment. 33 The most common AEs associated with DARA treatment were infusion-related reactions, which were generally observed during the first infusion and predominantly Grade 1/2 in intensity. 31, 34 In the monotherapy trials, prophylactic treatment was given, and infusion-related reactions were recorded in 43-50% of patients at the 16 mg/kg dose. 29, 31 The most frequent Grade 3/4 AEs with single-agent daratumumab were thrombocytopenia and pneumonia in the dose expansion part of the original trial, and anemia and thrombocytopenia in the SIRIUS trial. 29, 31 Of note, Grade ⩾ 3 thrombocytopenia and anemia occurred more frequently in patients who did not attain an objective response in the SIRIUS study, whereas there was no relationship between neutropenia and response. 31 In the combination study with LEN-DEX, the majority of Grade ⩾ 3 AEs were hematologic, and the maximum tolerated dose (MTD) of DARA was not reached. 35 DARA was also generally well tolerated in combination with alternate backbone regimens, with no major additional toxicity observed. 33 Phase III studies of LEN-DEX ± DARA (NCT02076009) and BORT-DEX ± DARA (NCT02136134) in patients with RRMM, and BORT-MEL-PRED ± DARA (NCT02195479) and LEN-DEX ± DARA (NCT02252172) in newly diagnosed patients with MM, have been announced.
SAR650984
SAR650984 is a humanized mAb generated from immunization with murine 300-19 cells transfected to express human CD38. 36 Similar to DARA, SAR650984 induces cell death via ADCC, ADCP and CDC in in vitro models. 36 ADCC was observed in all the CD38+ 112 lines tested, whereas the CDC activity was dependent on receptor density.
36 SAR650984 also elicited a direct pro-apoptotic effect, capable of inducing crosslinking-independent apoptosis in addition to the crosslinking-dependent apoptosis observed with DARA. 36, 37 Preclinical investigations also revealed that SAR650984 inhibited CD38 ectoenzyme activity, which has not been reported for DARA or MOR202.
37 SAR650984 has demonstrated synergistic or additive antitumor effects in combination with LEN, BORT, CAR and MEL in mouse xenograft tumor models. [38] [39] [40] Two ongoing phase I/II dose escalation studies are assessing SAR650984 in patients with RRMM: as a monotherapy (NCT01084252) or in combination with LEN and DEX (NCT01749969). In heavily pre-treated patients (median 6.5 prior lines of therapy including BORT, CAR, POM and LEN) who received single-agent SAR650984 0.3-20 mg/kg every other week, ORR was 27% overall, and 32% in patients who received SAR650984 at doses ⩾ 10 mg/kg 41 Table 1 ). PK data indicated decreased clearance of SAR650984 with increasing dose, suggestive of a dose relationship. 41 The MTD was not reached in this study, and additional dosing regimens are to be tested in the expansion phase of this study.
The combination therapy study, which also included heavily pre-treated patients (median seven prior treatment regimens), reported an ORR of 63% at SAR650984 doses of 10 mg/kg (Table 1) . 42 In addition, reductions in paraprotein of 490% were recorded in approximately one-third of patients at this dose. 42 In contrast to the combination trial of DARA with LEN-DEX, the vast majority of patients in this study were relapsed or refractory to LEN, yet the ORR was 48% in this patient subpopulation. 42 Notably, responses were also observed in patients refractory to BORT, CAR or POM. 43 The overall median PFS was 6.2 months, yet in patients who had received only one to two lines of prior therapy (n = 7) median PFS had not been reached at data cut-off. 42 The PK data indicated no significant interaction between LEN and SAR650984. 42, 43 As a monotherapy, the most common treatment-emergent AEs with SAR650984 were fatigue (53% of patients) and nausea (35%), and the most common drug-related Grade 3/4 event was pneumonia (8%). 41 Infusion reactions (52%) were observed during the first cycle of treatment, and were predominantly Grade 1/2 in severity. 41 Infusion reactions led to treatment discontinuation in two patients in the combination study, although these events decreased after Cycle 1 when prophylaxis was introduced. 42 In the combination study, the most common Grade 3/4 events were cytopenias, specifically neutropenia and thrombocytopenia. 42 
MOR202
MOR202 is a fully human HuCAL IgG1 antibody, which has been shown to elicit cell death by ADCC and ADCP. 44, 45 Preclinical data published to date have largely focused on MOR202 combination treatment, which has demonstrated that MOR202 antitumor activity is related to CD38 expression level, and is synergistic with POM and LEN and additive with BORT. [44] [45] [46] Of note, both LEN and POM treatment were shown to increase CD38 expression, and thus enhance the cytotoxic effects of MOR202. [44] [45] [46] In addition, treatment with both IMiDs induced activation of immune effector cells, further promoting ADCC and ADCP. 44, 46 These independent activities of LEN and POM suggest that the combination of CD38-targeted agents with IMiDs should provide a potent strategy for MM treatment. In vivo studies using murine MM models have also demonstrated synergistic reductions in bone lysis when MOR202 was combined with LEN, BORT or MEL. 47 Preliminary clinical data from a phase I/IIa study testing MOR202 with or without DEX in patients with RRMM have recently been reported. 48 Among 23 patients assessed, only one achieved a response better than stable disease (Table 1) . With the dosing schedule tested, the most common AEs were anemia, fatigue and nausea; the MTD of MOR202 was not reached in this study. Infusion-related reactions were observed in 31% of patients, yet only in those who received MOR202 alone, and these events occurred mostly during the first infusion. A transient antidrug antibody response to MOR202 was also observed in one patient. As part of the overall MOR202 development program, this mAb will also be evaluated in combination with LEN-DEX and POM-DEX in patients with RRMM. 48 Anti-CD38 mAb summary The anti-CD38 mAbs have shown potent activity in preclinical MM models both as single agents and in combination with other agents, with all three demonstrating ADCC and ADCP. ADCP may be particularly pertinent for treatment of MM, as high numbers of macrophages are present in the bone marrow. However, despite their similarities, there are also distinct differences between DARA, SAR650984 and MOR202. Each antibody targets a distinct epitope on CD38, 22, 37 and there are differences in their modes of action. For example, DARA induces crosslinking-dependent apoptosis, whereas SAR650984 can promote apoptosis with or without crosslinking. 49 Furthermore, SAR650984 is a much more potent inhibitor of CD38 ectoenzyme function than DARA or MOR202.
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This activity may provide another mechanism to suppress MM growth, based on the proposed role of CD38 ectoenzyme signaling in protecting MM cells in the bone marrow niche, although the clinical significance of such an activity is not clear. Combination therapy to date has focused on the addition of these mAbs to other novel agents, such as LEN which can enhance the activity of effector cells (for example, natural killer cells), and upregulate CD38 expression on MM cells. As receptor density impacts CDC for SAR650984 and DARA, and ADCC and ADCP for MOR202, LEN appears a natural partner for the anti-CD38 mAbs. Owing to their non-overlapping modes of action and distinct CD38-binding sites, the therapeutic combination of anti-CD38 mAbs is also conceivable.
The assessment of monoclonal immunoglobulin protein (M-protein) reduction by immunofixation electrophoresis is used to define the depth of response according to the International Myeloma Working Group criteria. 50 Therapeutic mAbs may interfere with this assay and thereby influence clinical interpretation of response to therapy. Data were recently presented for a DARA immunofixation electrophoresis reflex assay (DIRA), in which the binding of an anti-idiotypic antibody to DARA altered its electrophoretic migration and thus distinguished this mAb from the disease-associated M-protein in patient samples. 51 The use of such an assay may be necessary to confirm the reduction, and most specifically the absence (necessary for complete response (CR) 50 ), of M-protein in future mAb trials.
CS1/SLAMF7
CS1 is a member of the signaling lymphocyte activating-moleculerelated family and is highly expressed on the surface of normal plasma cells and MM cells. 52 This molecule is also expressed on other lymphocytes, for example natural killer cells, although at lower levels. CS1 is normally involved in regulating the immune response, 53 but appears to have a role in survival pathways in MM. 54 Elotuzumab (ELO) is a humanized IgG1 mAb directed against human CS1. 52 In preclinical models, ELO was shown to mediate cell death via ADCC and inhibit CS1-mediated MM cell adhesion to bone marrow stem cells, in a dose-dependent manner. 55 In addition, ELO may act beyond ADCC by enhancing the cytotoxic activity of natural killer cells. 56 Despite the promising preclinical data, a phase I clinical trial of ELO in patients with RRMM demonstrated that this agent was not effective as a monotherapy. 57 Indeed, no objective responses were observed during the study and~75% of patients had progressive disease. 57 However, ELO at doses up to 20 mg/kg every other week was generally well tolerated, 57 supporting its investigation as a part of a combination regimen.
In a phase I study of ELO plus BORT in patients with RRMM, the ORR was 48% (Table 1) , including responses in two of three patients previously refractory to BORT. 58 This level of response was also attained in 7 of 10 patients with high-risk cytogenetics. 58 ELO-BORT-DEX was compared with BORT-DEX alone in a phase II trial, which demonstrated that, despite a similar ORR (65 vs 63%), the triplet regimen improved median PFS (9.7 months vs 6.9 months) over BORT-DEX alone in patients with RRMM. 59 ELO has also been tested in a phase II trial with THAL and DEX in patients with RRMM, with an ORR of 40% reported. 60 The majority of clinical data for ELO, however, has been attained in combination with LEN and DEX, with this triplet regimen tested in moderately pre-treated patients with RRMM in phase I, II and III trials. The phase I study demonstrated the tolerability and activity (ORR, 82%) of ELO-LEN-DEX 61 with the 10 and 20 mg/kg ELO doses advanced to phase II. In a LEN-naive patient population, an overall ORR of 84% (61/73) was reported in the phase II study. 62 However, efficacy appeared better in the 10 mg/kg cohort compared with the 20 mg/kg cohort, both in terms of ORR (92 vs 76%) and PFS (33 months vs 18.6 months). 62 As expected, ORR and median PFS were reduced in patients with ⩾ 2 previous therapies compared with those who had received only one prior therapy (ORR, 78 vs 91%; PFS, 21.3 months vs 25.0 months), 63 although these were the first data from a mAb study to demonstrate the impact of pre-treatment level on response. Comparison of response rates between different agents should thus take account of the number of lines of prior therapy. With the improved efficacy data at 10 mg/kg compared with 20 mg/kg, this lower dose was tested in 646 patients with RRMM in the recently reported phase III ELOQUENT-2 study. In a population who had received a median of two prior therapies (6% had received LEN), ELO-LEN-DEX significantly extended median PFS (co-primary end point) compared with LEN-DEX alone (19.4 months vs 14.9 months; hazard ratio, 0.57-0.85; P o 0.0001). 64 The benefit of ELO-LEN-DEX with respect to PFS was maintained in patients o65 and ⩾ 65 years, and in patients with the del(17p) and t (4;14) abnormalities. 64 The 1-year PFS rate was higher in the ELO-LEN-DEX arm (68 vs 57%), and this difference was slightly greater at 2 years (41 vs 27%). 64 ELO-LEN-DEX also improved ORR (co-primary end point) compared with LEN-DEX (79 vs 66%; Po 0.0001) 64 (Table 1) ; PFS was longer in patients who achieved at least PR with ELO-LEN-DEX than with LEN-DEX alone. 64 The OS data were immature at the time of presentation.
As a single agent, the most common treatment-emergent AEs reported with ELO were chills and pyrexia, which were mostly Grade 1/2 in severity. 57 Approximately 30% (10/34) of patients developed an infection during ELO therapy, although only 3/10 cases were considered related to ELO. 57 In patients who received BORT and ELO in the phase II trial, the most frequent Grade ⩾ 3 events were thrombocytopenia and infections, although the rate of thrombocytopenia was slightly lower with ELO-BORT-DEX compared with BORT-DEX alone (9 vs 17%). 59 Cytopenias were the most common Grade ⩾ 3 event when ELO was combined with LEN-DEX, 62, 64 and were also observed with the ELO-THAL-DEX regimen, 60 potentially due to the IMiDs used in these combinations. The most frequently observed non-hematologic Grade ⩾ 3 events with ELO plus THAL-DEX were asthenia, peripheral edema and fever. 60 Infusion reactions were managed using prophylactic medication in the phase II and III combination regimens; these events occurred in~10% of patients in the studies of ELO with LEN-DEX, BORT-DEX and THAL-DEX, and were mostly Grade 1/2 in intensity. 59, 60, 63, 64 The ELO combination regimens appear more effective in patients who have received fewer lines of treatment, and a phase III trial of LEN-DEX ± ELO is ongoing in patients with previously untreated MM (ELOQUENT-1; NCT01335399). Other ELO-based regimens are being tested, with encouraging initial safety data recently reported for ELO-LEN-BORT-DEX in newly diagnosed, high-risk patients, 65 and a trial of ELO in combination with lirilumab (mAb that blocks interaction between killer-cell immunoglobulin receptors and their ligands 66 ) or urelumab (anti-CD137 mAb that stimulates immune response 67 ) currently recruiting (NCT02252263). Furthermore, a trial of single-agent ELO in patients with smoldering MM is planned (NCT01441973).
INTERLEUKIN-6
IL-6 is involved in the survival and proliferation of MM cells, 68, 69 with a key role proposed during the early stages of disease development. 70, 71 Siltuximab, a chimeric mAb against IL-6, has been shown to sensitize MM cells to DEX-mediated apoptosis 72 and to enhance the activity of BORT and MEL, in preclinical models. 73, 74 In combination with DEX, siltuximab was well tolerated but demonstrated only modest efficacy in patients with RRMM (ORR, 11%); as a single agent, siltuximab did not induce any objective responses. 75 The benefit of adding siltuximab to BORT was also tested in BORT-naive patients with RRMM, but although ORR increased with the combination regimen (ORR, 55 vs 47%), there was no improvement in PFS or OS compared with BORT-placebo. 76 As patients with RRMM may have residual MM cells that are less dependent on IL-6, siltuximab was tested in patients with newly diagnosed MM in a phase II study: siltuximab-BORT-MEL-PRED vs BORT-MEL-PRED. An EBMT ORR (PR+CR) of 88% was reported in patients who received siltuximab-BORT-MEL-PRED compared with 80% in the comparator arm, but the study did not meet its primary end point as the difference in CR rate between the study arms was o 10%. 77 The very good PR rate was significantly increased in the siltuximab arm, although this did not translate to differences in OS or PFS, raising questions over the association between this level of response and outcomes. 77 The incidence of Grade ⩾ 3 events was slightly higher in the siltuximab arm (92 vs 81%), with an increased rate of hematologic events and infections. 77 The possibility that IL-6 is involved during early MM development has also led to initial testing of siltuximab in patients with monoclonal gammopathy of undetermined significance or smoldering myeloma. Here, single-agent siltuximab reduced paraprotein in a subset of patients and did not yield any new safety signals. 78 As such, siltuximab is being tested against placebo in a phase II trial in patients with high-risk smoldering myeloma (bone marrow plasma cells ⩾ 10% and either serum monoclonal protein ⩾ 3 g/dl, or abnormal free light chain ratio o0.126 or 48, and serum M-protein o3 g/dl but ⩾ 1 g/dl) (NCT01484275).
B-CELL ACTIVATING FACTOR
B-cell activating factor (BAFF) is a member of the tumor necrosis factor superfamily that is produced in the bone marrow, and is overexpressed in MM cells compared with normal plasma cells at the transcript level. 79 BAFF appears to promote survival of MM cells and protect them from DEX-induced apoptosis.
80 Tabalumab (LY2127399) is a human mAb against BAFF that neutralizes the membrane-bound and soluble forms of this factor. 81 In a phase I study in patients with RRMM (patients were not refractory to BORT), the combination of tabalumab with BORT-DEX achieved an ORR of 46%. 82 Treatment discontinuation was reported owing to neuropathy, neuralgia, fatigue and thrombocytopenia. 82 A phase II trial of tabalumab (100 or 300 mg) -BORT-DEX vs placebo-BORT-DEX has been completed (NCT01602224), although results have yet to be reported.
CD74
CD74 is a major histocompatibility complex class II chaperone involved in antigen presentation. It is also frequently expressed in MM cell lines and in the malignant plasma cells of patient samples, 83 and is an attractive target based on its rapid internalization. 84 Milatuzumab (hLL1) is a humanized anti-CD74 mAb that, when crosslinked, has shown anti-proliferative activity against MM cells both alone or in combination treatments in preclinical models. 85 In a phase I dose escalation study in heavily pre-treated patients with RRMM (median five prior treatments), the best response achieved with 4 weeks' milatuzumab monotherapy was stable disease. 86 Modifications to infusion time and prophylactic treatment appeared to improve the tolerability of this agent, which was otherwise generally well tolerated. 86 A phase I/II trial of milatuzumab conjugated with doxorubicin is ongoing in patients with RRMM (NCT01101594).
CD138
CD138/syndecan-1 is expressed during B-cell development, and is specifically located on plasma cells and MM cells in the bone marrow. 87 Indatuximab ravtansine (BT062) comprises a mAb against CD138 conjugated to the cytotoxic maytansinoid DM4. 88 As a monotherapy, indatuximab ravtansine treatment achieved at least PR in only 4% (1/27) of patients with RRMM, but was generally well tolerated. 89 As a combination therapy with LEN-DEX, an ORR of 78% was attained and acceptable tolerability maintained in a moderately pre-treated RRMM population (median of three prior therapies). 90 This trial is ongoing, although no future trials of indatuximab ravtansine have been announced. Elsewhere, a [
213 Bi] radiolabelled antibody against CD138 is in preclinical development. 91 PD-1/PD-L1 PD-1 is expressed on the surface of T and B cells, and inhibits T-cell activation and proliferation through its interaction with the PD-L1 ligand expressed on antigen-presenting cells. 92, 93 PD-1/PD-L1 signaling is dysregulated in patients with MM, with PD-L1 expressed on MM cells, and PD-1 expressed on natural killer cells and upregulated on T cells. 94 Thus, the PD-1/PD-L1 signaling axis provides a mechanism through which MM cells can interfere with the immune response and avoid death ( Figure 3 ). The use of mAbs targeting PD-1/PD-L1 has been tested in the preclinical setting, with anti-myeloma activity demonstrated using an anti-PD-L1-based treatment protocol. 95 The anti-PD-1 mAb most advanced in the clinic is nivolumab, although monotherapy with this agent has thus far achieved only disease stabilization (no objective responses reported) in patients with RRMM. 96 However, nivolumab was shown to be tolerable, and its combination with the CTLA-4 mAb ipilimumab (activation of CTLA-4 dampens the host T-cell response 97 ) or lirilumab is under assessment as part of the same phase I trial (NCT01592370). In addition, early-stage clinical trials of the anti-PD-1 antibodies pembrolizumab (MK-3475) and pidilizumab, typically in combination with IMiDs, are ongoing in patients with RRMM.
OTHER ANTIGENS
Immunophenotyping of MM cells has also revealed a number of other target antigens (Figure 1) , and to date, mAbs to CD40, CD56, ICAM-1 and CXCR4 have been tested in clinical studies. Dacetuzumab and lucatumumab, mAbs to the tumor necrosis factor superfamily member CD40, had good tolerability but only weak efficacy as single agents 98, 99 (Table 1 ). In addition, only modest ORR (39%) was attained when dacetuzumab was combined with LEN-DEX in patients with RRMM. 100 Development of dacetuzumab has been discontinued, and no upcoming trials of lucatumumab have been reported in the MM setting.
Lorvotuzumab mertansine, a humanized mAb to CD56 conjugated to the cytotoxic maytansinoid derivative DM1, also displayed low activity as a monotherapy in patients with RRMM (ORR, 7%; Table 1) . 101 In combination with LEN-DEX, an ORR of 56% was achieved in patients with CD56+ RRMM, although this population had received only a median of two prior anti-myeloma therapies.
102,103 Dose-related neuropathy was observed in both the monotherapy and combination therapy studies, 101, 102 and no new trials have been announced for lorvotuzumab mertansine.
Clinical data from a phase I trial of BI-505, a human mAb against ICAM-1, demonstrated that this agent can stabilize disease, although no objective responses were observed following 2 months' treatment of patients with RRMM (Bioinvent press release). However, this agent was generally well tolerated and a phase II study of single-agent BI-505 in patients with smoldering myeloma is now recruiting (NCT01838369). Similar to the above agents, the anti-CXCR4 mAb ulocuplumab is also under investigation in patients with RRMM, in combination with either LEN-DEX or BORT-DEX (NCT01359657). The ORR was 55% and 40% for the LEN-DEX and BORT-DEX groups, respectively, and an increase in circulating lymphocytes was observed after each ulocuplumab infusion at the two highest doses tested. 104 Both combination regimens were generally well tolerated, with the MTD not reached during the dose escalation phase of this study. 104 
CONCLUSIONS
The introduction of PIs and IMiDs has improved outcomes for patients with MM, although these agents do not cure the disease and most patients will eventually relapse. As such, the need remains for newer agents with novel modes of action. Inspiration has been derived from knowledge of molecules expressed on the surface of myeloma cells, with a number of targets identified for mAb-based therapies. Of those agents which have reported clinical data, the anti-CD38 mAbs DARA and SAR650984 have shown robust single-agent activity, which has been enhanced through the addition of LEN-DEX, whereas the activity of other agents (for example, ELO) appears restricted to combination regimens. The antibodies discussed here are generally well tolerated, and importantly most appear to have a safety profile that is distinct from current treatments. Combination therapy is thus a viable strategy, and in this regard LEN may have an inherent advantage due to its demonstrated positive effects on the immune responses through which a number of the mAbs operate. However, other combinations are under clinical testing, and the potential remains for combining the antibodies themselves providing that the modes of action are distinct. High response rates have been achieved in patients with RRMM with combination therapy, in some cases even in heavily pre-treated patients. However, these agents may also have a role in early-line therapy, with data from other novel agents suggesting increased ORR and deeper responses can be achieved in front-line therapy compared with treatment of RRMM. 105, 106 As treatment paradigms shift, mAb therapy may also be utilized for patients with monoclonal gammopathy of undetermined significance or smoldering MM; toxicities associated with current regimens for symptomatic MM may deter their use in these patients, although a tolerable, efficacious mAb monotherapy would not face the same issues. Here, it is notable that single-agent clinical studies of both DARA and ELO in patients with smoldering MM have been announced. The development of mAbs thus represents an exciting new chapter in the battle against MM. Future data from larger studies will reveal how much of an impact these agents will make on long-term survival and the quality of life in patients with MM.
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